AdvanCell secured an oversubscribed $315 million Series D financing to advance its radiopharmaceutical program and expand manufacturing capacity. The round is described as targeting late-stage development while addressing a persistent bottleneck across radiopharma: isotope supply and production scalability. The company’s lead asset, ADVC-001, is a lead-212 prostate-specific membrane antigen (PSMA)-targeted radioligand therapy for metastatic castration-resistant prostate cancer. With the financing tied to both clinical progression and infrastructure buildout, the deal underscores how investors are increasingly underwriting execution risk in radiopharma—not just trial performance.